Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy of SPI-1005 in Meniere's Disease

Trial Profile

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy of SPI-1005 in Meniere's Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ebselen (Primary)
  • Indications Meniere's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sound Pharmaceuticals
  • Most Recent Events

    • 18 Sep 2019 According to a Sound Pharmaceuticals media release, on the basis of this and othe study (263174), the FDA's Division of Neurology Products has granted Fast Track Designation to SPI-1005 in the treatment of Meniere's Disease.
    • 25 Jun 2019 According to a Sound Pharmaceuticals media release, more detailed presentation of the ITT and Per-Protocol analyses will occur at a scientific meeting later in 2019.
    • 25 Jun 2019 Topline results at week-8 published in the Sound Pharmaceuticals Media Release
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top